250 related articles for article (PubMed ID: 19709689)
1. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
Oz Gul O; Tuncel E; Yilmaz Y; Ulukaya E; Gul CB; Kiyici S; Oral AY; Guclu M; Ersoy C; Imamoglu S
Metabolism; 2010 Jan; 59(1):64-9. PubMed ID: 19709689
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
Koyama H; Tanaka S; Monden M; Shoji T; Morioka T; Fukumoto S; Mori K; Emoto M; Shoji T; Fukui M; Fujii H; Nishizawa Y; Inaba M
Atherosclerosis; 2014 Jun; 234(2):329-34. PubMed ID: 24727234
[TBL] [Abstract][Full Text] [Related]
4. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
6. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
8. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Chogtu B; Singh NP; Chawla S; Gupta U
Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Chiquette E; Ramirez G; Defronzo R
Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
[TBL] [Abstract][Full Text] [Related]
11. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
12. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
Sharma SK; Verma SH
J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
[TBL] [Abstract][Full Text] [Related]
13. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.
Brackenridge AL; Jackson N; Jefferson W; Stolinski M; Shojaee-Moradie F; Hovorka R; Umpleby AM; Russell-Jones D
Diabet Med; 2009 May; 26(5):532-9. PubMed ID: 19646194
[TBL] [Abstract][Full Text] [Related]
16. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Doggrell SA
Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
[TBL] [Abstract][Full Text] [Related]
20. Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Vergès B
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():15-8. PubMed ID: 18001314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
